In-clinic Celution Opportunity to partner with rheumatology, plastic surgery and hand surgery clinics to deploy Cytori Celution in-clinic cell therapy for scleroderma hand dysfunction, leveraging the lead product candidate and the Celution instrument and consumables.

Ortho and Burns The pipeline includes therapies for thermal burns, hip osteonecrosis and knee osteoarthritis; pursue partnerships with orthopedic and burn centers to run trials, pilot programs, and adopt Celixir therapy, enabling cross-sell to multiple surgical specialties.

International Expansion US and Japan studies indicate potential for international licensing or co-development deals; target regional partners for distribution, regulatory support, and commercialization, while leveraging interest shown in pursuing EMA pathways for related products.

Financing Partnerships Existing Oxford Finance loan extension suggests lender interest and potential for additional financing; explore debt financing, equipment funding, and strategic investment with financial partners to accelerate trials and device deployment.

Pipeline Leverage Cytori’s broader portfolio including ECCS-50 Habeo, ATI-0918, Cytori Nanomedicine, and the Azaya Therapeutics acquisition offers licensing or co-development opportunities to monetize assets and broaden the addressable market.